Press Releases Immutep ADR Deutsche Boerse AG

Equities

YP1A

US45257L1089

Market Closed - Deutsche Boerse AG Other stock markets 07:09:28 2024-07-11 am EDT			5-day change	1st Jan Change
1.76 ^EUR	-1.68%		-2.22%	-16.98%

Jun. 28	Immutep Reports Positive Topline Results from TACTI-003 Phase IIb Trial in First Line Head and Neck Cancer	CI
Jun. 27	ADRs End Flat; Alarum Technologies Climbs 26%	DJ

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immutep : Global Webcast Slides for TACTI 003 Positive Data in Patients with Negative PD L1 Expression (Cohort B)	07:15pm	PU
Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression	06:41pm	AQ
Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results	Jul. 03	AQ
Immutep Reports Positive Topline Results from TACTI-003 Phase IIb Trial in First Line Head and Neck Cancer	Jun. 28	AQ
Immutep Limited (IMM) \| TACTI-003: the real results; Maintain Overweight A$1.13 PT (Analysts: Dr Melissa Benson and Dr Shane Storey)	Jun. 26	PU
Immutep : Global Webcast Slides for New Efti Clinical Data in 1st Line HNSCC	Jun. 26	PU
Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer	Jun. 25	AQ
Immutep : successfully completes institutional placement and institutional component of entitlement offer	Jun. 05	PU
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial	Jun. 02	AQ
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024	May. 15	AQ
Immutep : ESMO Breast 2024 AIPAC 003 Poster (Metastatic Breast Cancer)	May. 14	PU
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	May. 02	AQ
Immutep Quarterly Activities Report Q3 FY24	Apr. 29	AQ
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761	Apr. 18	AQ
Wilsons - Adding Autoimmune to the indication list; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)	Apr. 18	PU
Immutep : Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP76	Apr. 17	PU
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	Apr. 17	AQ
Immutep : Corporate Presentation	Mar. 26	PU
Ladenburg Thalmann - Next Is Dose Optimization for BC Program; Reiterate Buy, $8.30 PT (Analyst: Ahu Demir, PhD)	Mar. 05	PU
Wilsons - Dose it higher? Now an option; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)	Mar. 05	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Immutep ADR Deutsche Boerse AG

Equities

YP1A

US45257L1089

Press Releases

Filters